Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Current Leases (2023 - 2025)

bioAffinity Technologies (BIAF) has disclosed Current Leases for 3 consecutive years, with $136197.0 as the latest value for Q3 2025.

  • On a quarterly basis, Current Leases fell 64.88% to $136197.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $136197.0, a 64.88% decrease, with the full-year FY2024 number at $395301.0, up 317.39% from a year prior.
  • Current Leases was $136197.0 for Q3 2025 at bioAffinity Technologies, up from $133239.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $403584.0 in Q1 2025 to a low of $94708.0 in Q4 2023.
  • A 3-year average of $264496.8 and a median of $358282.0 in 2023 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: soared 317.39% in 2024, then tumbled 64.88% in 2025.
  • bioAffinity Technologies' Current Leases stood at $94708.0 in 2023, then skyrocketed by 317.39% to $395301.0 in 2024, then tumbled by 65.55% to $136197.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Current Leases are $136197.0 (Q3 2025), $133239.0 (Q2 2025), and $403584.0 (Q1 2025).